These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20179673)

  • 1. Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.
    Bernard D; Ventresca MS; Marshall LA; Evelegh C; Wan Y; Bramson JL
    Mol Ther; 2010 Jun; 18(6):1224-32. PubMed ID: 20179673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies.
    Protti MP; De Monte L; Di Lullo G
    Tissue Antigens; 2014 Apr; 83(4):237-46. PubMed ID: 24641502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCA587 Protein Vaccine Induces Specific Antitumor Immunity Mediated by CD4
    Yang W; Zhang W; Wang X; Tan L; Li H; Wu J; Wu Q; Sun W; Chen J; Yin Y
    Anticancer Agents Med Chem; 2021; 21(6):738-746. PubMed ID: 32723258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.
    Ossendorp F; Mengedé E; Camps M; Filius R; Melief CJ
    J Exp Med; 1998 Mar; 187(5):693-702. PubMed ID: 9480979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4
    Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
    Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo.
    Fallarino F; Grohmann U; Bianchi R; Vacca C; Fioretti MC; Puccetti P
    J Immunol; 2000 Nov; 165(10):5495-501. PubMed ID: 11067902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes.
    Chen PW; Ullrich SE; Ananthaswamy HN
    J Leukoc Biol; 1994 Oct; 56(4):469-74. PubMed ID: 7930943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
    Wang XY; Kazim L; Repasky EA; Subjeck JR
    Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 T cell-mediated masking effects of the immunogenicity of tumor-associated antigens are qualitatively and quantitatively different depending on the individual antigens.
    Okano S; Matsumoto Y; Yoshiya S; Yamashita Y; Harimoto N; Ikegami T; Shirabe K; Harada M; Yoshikai Y; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Jan; 104(1):1-14. PubMed ID: 23600320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells.
    Cheng TY; Wu JT; Lin RH
    Int Immunol; 1998 Oct; 10(10):1397-406. PubMed ID: 9796906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion.
    Tanaka Y; Koido S; Xia J; Ohana M; Liu C; Cote GM; Sawyer DB; Calderwood S; Gong J
    J Immunol; 2004 Jun; 172(12):7848-58. PubMed ID: 15187169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.